drugset / Trial / NCT07634510

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205

NCT07634510 ↗

Phase 1 Not yet recruiting 37 enrolled Shanghai Minwei Biotechnology Co., Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being done to test a new injection called MWX205 in people with high cholesterol or fat levels in the blood (dyslipidemia). Researchers will check if a single dose of MWX205 is safe and how the body reacts to it. They will also measure how quickly the drug enters the bloodstream and how long it stays in the body, and compare it with a placebo (inactive treatment). The study will help decide the right dose and understand how this medicine could be used in future treatments. The main questions this study aims to answer are: 1. Is MWX205 safe after a single dose? 2. How does the body process MWX205? 3. Does MWX205 show any effect on the body related to cholesterol levels?

Timeline

Start
2026-06-22
Primary completion
2026-10-26
Completion
2027-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject MWX205 Oligonucleotide (other) 50 mg Subcutaneous
Subject MWX205 Oligonucleotide (other) 200 mg Subcutaneous
Subject MWX205 Oligonucleotide (other) 400 mg Subcutaneous
Subject MWX205 Oligonucleotide (other) 800 mg Subcutaneous
Subject MWX205 Oligonucleotide (other) 1200 mg Subcutaneous

Indications